Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–90.

Article  PubMed  PubMed Central  Google Scholar 

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.

Article  CAS  PubMed  Google Scholar 

Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279–86.

Article  PubMed  Google Scholar 

Thurman DJ, Logroscino G, Beghi E, Hauser WA, Hesdorffer DC, Newton CR, et al. The burden of premature mortality of epilepsy in high-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58:17–26.

Article  PubMed  Google Scholar 

Devinsky O, Spruill T, Thurman D, Friedman D. Recognizing and preventing epilepsy-related mortality: a call for action. Neurology. 2016;86:779–86.

Article  PubMed  PubMed Central  Google Scholar 

Mula M, Coleman H, Wilson SJ. Neuropsychiatric and cognitive comorbidities in epilepsy. Continuum (Minneap Minn). 2022;28:457–82.

PubMed  Google Scholar 

Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia. 2011;52:2168–80.

Article  PubMed  Google Scholar 

Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19:544–56.

Article  CAS  PubMed  Google Scholar 

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med [Internet]. 2000;342:314–9. https://doi.org/10.1056/NEJM200002033420503.

Janmohamed M, Hakeem H, Ooi S, Hakami S, Vu L, Perucca P, et al. Treatment outcomes of newly diagnosed epilepsy: a systematic review and meta-analysis. CNS Drugs. 2023;37:13–30.

Article  PubMed  Google Scholar 

Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606–38.

Article  PubMed  PubMed Central  Google Scholar 

Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301.

Article  PubMed  PubMed Central  Google Scholar 

Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012;64:930–42.

Article  CAS  PubMed  Google Scholar 

Schmidt D, Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009;9:47–52.

Article  PubMed  Google Scholar 

Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35:935–63.

Article  PubMed  PubMed Central  Google Scholar 

Ben-Menachem E, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Am Acad Neurol. 2016.

Rademacher M, Toledo M, Van Paesschen W, Liow KK, Milanov IG, Esch M-L, et al. Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: results from two double-blind, randomized, placebo-controlled trials. Epilepsia Open. 2022;7:758–70.

Article  PubMed  PubMed Central  Google Scholar 

Löscher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62:596–614.

Article  PubMed  Google Scholar 

Chung S, French J, Kowalski J, Krauss G, Sang KL, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94.

Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19.

Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280–91.

Article  PubMed  Google Scholar 

Steinhoff B, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–9.

Article  CAS  PubMed  Google Scholar 

Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142:91–107.

Article  PubMed  Google Scholar 

Sperling MR, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62:3005–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenfeld WE, Ferrari L, Kamin M. Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;183: 106940.

Article  CAS  PubMed  Google Scholar 

Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99:e989–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62:3016–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenfeld WE, Ferrari L, Kerr WT, Sperling MR. Sudden unexpected death in epilepsy during cenobamate clinical development. Epilepsia. 2023.

Krauss G, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38–48.

Article  CAS  PubMed  Google Scholar 

Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61:1099–108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705–20.

Article  PubMed  PubMed Central  Google Scholar 

SK Life Sciences. Data on file.

Ferrari L, Rosenfeld WE, Kamin M. A global update on cenobamate based on real-world experience in over 100 000 patients. Epilepsia. 2024;65:1149–50.

Article  CAS  PubMed  Google Scholar 

Bayat A, Hjalgrim H, Møller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015;56:e36–9.

Article  CAS  PubMed  Google Scholar 

Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43–7.

Article  PubMed